Rigel Pharmaceuticals reaffirms FY25 revenue $200M-$210M, consensus $197.79M

Sees FY25 net product sales $185M-$192M; and contract revenues from collaborations $15M-$18M. The company added, “The revenue ranges above exclude approximately $40.0 million in non-cash revenue that Rigel expects to recognize in the Q2 related to the release of the remaining cost share liability from Rigel’s collaboration with Lilly for the development and commercialization of ocadusertib. The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.”